Celcuity (CELC) Non Operating Income (2016 - 2026)
Celcuity's (CELC) quarterly Non Operating Income came in at -$1.8 million in Q4 2025, down 694.62% YoY from $298006.0 in Q4 2024, and down 85.55% on a QoQ basis from -$955000.0 in Q3 2025.
Celcuity (CELC) Non Operating Income (2016 - 2026) Analysis & Trends
Celcuity (CELC) has 9 years of Non Operating Income data on file, last reported at -$1.8 million in Q4 2025.
- Quarterly Non Operating Income fell 694.62% year-over-year to -$1.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$4.8 million (down 425.94% YoY) and the FY2025 annual result came in at -$4.8 million, down 425.94% from the prior year.
- Non Operating Income eased to -$1.8 million in Q4 2025, from -$955000.0 in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $881000.0 in Q1 2024 to a low of -$1.8 million in Q4 2025.
- A 4-year average of -$368362.2 and a median of -$359799.0 in 2022 frame the typical range for Non Operating Income.
- Annual changes were most pronounced in 2021 — Non Operating Income sank 7499.34% — and 2022, when it jumped 41.48%.
- Tracing CELC's Non Operating Income over 4 years: stood at -$427460.0 in 2021, then surged by 41.48% to -$250166.0 in 2022, then climbed by 10.86% to -$223000.0 in 2024, then sank by 694.62% to -$1.8 million in 2025.
- The last three Non Operating Income figures came in at -$1.8 million (Q4 2025), -$955000.0 (Q3 2025), and -$1.3 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Celcuity | 4.50 Bn | 4.50 Bn | - | -12.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -12.75 Mn |
| Dec 31, 2025 | -1.77 Mn |
| Sep 30, 2025 | -955,000.00 |
| Jun 30, 2025 | -1.26 Mn |
| Mar 31, 2025 | -864,000.00 |
| Dec 31, 2024 | -223,000.00 |
| Sep 30, 2024 | 268,000.00 |
| Jun 30, 2024 | 562,000.00 |
| Mar 31, 2024 | 881,000.00 |
| Sep 30, 2022 | -250,166.00 |
| Jun 30, 2022 | -359,799.00 |
| Sep 30, 2021 | -427,460.00 |
| Jun 30, 2021 | -389,384.00 |
| Mar 31, 2021 | 101.00 |
| Dec 31, 2020 | 443.00 |
| Sep 30, 2020 | 5,777.00 |
| Jun 30, 2020 | 11,952.00 |
| Mar 31, 2020 | 63,818.00 |
| Dec 31, 2019 | 88,739.00 |
| Sep 30, 2019 | 107,061.00 |